The deal will enable BD to support health care providers move closer to the One-Stick Hospital Stay vision
BD has acquired needle-free blood draw technology provider Velano Vascular. (Credit: BD)
Becton, Dickinson and Company (BD) has acquired San Francisco-based needle-free blood draw technology provider Velano Vascular for an undisclosed sum.
Velano’s needle-free technology allows blood draws from existing peripheral intravenous catheter (PIVC) lines.
It will help health care providers to eliminate multiple needlesticks for blood sample collection, minimise the pain and discomfort from the process.
Velano Vascular co-founder Dr Eric Stone said: “By joining forces with BD, we can collectively accelerate the impact of our work to more rapidly make this shared vision of a ‘One-Stick Hospital Stay’ a reality.”
Velano Vascular provides PIVO device, which already secured approval from the US Food and Drug Administration (FDA).
The PIVO device will enable BD to support health care providers move closer to the aspirational vision of the one-stick hospital stay, thereby helping to provide only one stick to certain low-acuity patients for their entire hospital stay.
BD medication delivery solutions president Rick Byrd said: “As a global leader in vascular access solutions and blood collection, BD has been on the forefront of innovations that improve the patient experience and reduce additional needlesticks.
“Now, with the addition of Velano and its groundbreaking technologies, we can envision a world where a ‘One-Stick Hospital Stay’ could be a reality for many by making the numerous inpatient blood draws better for everyone.”
BD already offers Vacutainer blood specimen collection portfolio, which consists of products for both capillary and venous blood draw.
The firm’s comprehensive vascular access management solutions will enable clinicians to select the right device for the right patient to achieve first-stick success for starting IV lines and minimise IV complications.
In May this year, BD announced plans to spin off its diabetes care business into an independent and publicly-traded company.